Prolongation of HCV Treatment to 18 Months Reduces Relapse Rates From 40 to 15 Percent
Treatment of chronic hepatitis C with interferon can be ineffective due to relapse. We aimed to reduce the 40% relapse rate of 6 months interferonribavirin combination therapy by prolonging treatment to 18 months.
Three hundred patients with treatment-naive hepatitis C, were randomized to 18 months combination therapy with interferon (3 MU tiw) and ribavirin (10001200 mg/day), 18 months interferon combined with placebo, or 6 months combination therapy with interferon and ribavirin, in a double blinded manner. All 295 patients who received at least one dose of treatment were included in the intention to treat analysis.
J T Brouwer and others. Reduction of relapse rates by 18-month treatment
in chronic hepatitis C. A Benelux randomized trial in 300 patients. Journal
of Hepatology 40(4): 689-695. April 2004.
|Print this page Previous Page|
is hepatitis? | Our
Mission | Who's
Involved | Hepatitis
C News | Upcoming
Events | Brochures
HCV Awareness Items | Related Links | From the CEO | To Whom It May Concern |
Bulletins | Message Board | Webrings & Awards | Contact Information
|Copyright © Hepatitis C Association Inc. All rights reserved.|